<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />



<meta name="date" content="2026-02-13" />

<title>ZYDUSLIFE</title>

<script src="rmdlib/header-attrs-2.30/header-attrs.js"></script>
<script src="rmdlib/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="rmdlib/bootstrap-3.3.5/css/flatly.min.css" rel="stylesheet" />
<script src="rmdlib/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="rmdlib/navigation-1.1/tabsets.js"></script>
<script src="rmdlib/accessible-code-block-0.0.1/empty-anchor.js"></script>
<link href="rmdlib/font-awesome-6.4.0/css/all.min.css" rel="stylesheet" />
<link href="rmdlib/font-awesome-6.4.0/css/v4-shims.min.css" rel="stylesheet" />
<meta name="description" content="Indian equities analysis, margin reports, risk, etc..." />
<meta property="og:image" content="https://avatars3.githubusercontent.com/u/21966469?s=400&v=4" />

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>










<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
details > summary > p:only-child {
  display: inline;
}
pre code {
  padding: 0;
}
</style>


<style type="text/css">
.dropdown-submenu {
  position: relative;
}
.dropdown-submenu>.dropdown-menu {
  top: 0;
  left: 100%;
  margin-top: -6px;
  margin-left: -1px;
  border-radius: 0 6px 6px 6px;
}
.dropdown-submenu:hover>.dropdown-menu {
  display: block;
}
.dropdown-submenu>a:after {
  display: block;
  content: " ";
  float: right;
  width: 0;
  height: 0;
  border-color: transparent;
  border-style: solid;
  border-width: 5px 0 5px 5px;
  border-left-color: #cccccc;
  margin-top: 5px;
  margin-right: -10px;
}
.dropdown-submenu:hover>a:after {
  border-left-color: #adb5bd;
}
.dropdown-submenu.pull-left {
  float: none;
}
.dropdown-submenu.pull-left>.dropdown-menu {
  left: -100%;
  margin-left: 10px;
  border-radius: 6px 0 6px 6px;
}
</style>

<script type="text/javascript">
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark the anchor link active (and if it's in a dropdown, also mark that active)
  var dropdown = menuAnchor.closest('li.dropdown');
  if (window.bootstrap) { // Bootstrap 4+
    menuAnchor.addClass('active');
    dropdown.find('> .dropdown-toggle').addClass('active');
  } else { // Bootstrap 3
    menuAnchor.parent().addClass('active');
    dropdown.addClass('active');
  }

  // Navbar adjustments
  var navHeight = $(".navbar").first().height() + 15;
  var style = document.createElement('style');
  var pt = "padding-top: " + navHeight + "px; ";
  var mt = "margin-top: -" + navHeight + "px; ";
  var css = "";
  // offset scroll position for anchor links (for fixed navbar)
  for (var i = 1; i <= 6; i++) {
    css += ".section h" + i + "{ " + pt + mt + "}\n";
  }
  style.innerHTML = "body {" + pt + "padding-bottom: 40px; }\n" + css;
  document.head.appendChild(style);
});
</script>

<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before, .tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "\e259";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "\e258";
  font-family: 'Glyphicons Halflings';
  border: none;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->




</head>

<body>


<div class="container-fluid main-container">




<div class="navbar navbar-inverse  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-bs-toggle="collapse" data-target="#navbar" data-bs-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">StockViz</a>
    </div>
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        <li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-globe"></span>
     
    Macro
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-bnd.html">Fixed Income</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cur.html">Currencies</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cmdy.html">Commodities</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-arrows-v"></span>
     
    52w H&amp;L
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-rocket"></span>
     
    ATH
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-magnet"></span>
     
    Drawdowns
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-train"></span>
     
    Streaks
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-hand-pointer-o"></span>
     
    Indian Indices
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-risk.html">Performance Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-IN.html">Index Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-MKT-CAP.html">Classification Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-industry.html">Industry Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-syn.html">Synthetic Indices</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-vol-NIFTY.html">NIFTY Volatility</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-valuations.html">Valuations</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/results-IN.html">Result Dates</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/eq-in/rp-margin.html">Margin Report</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-shopping-bag"></span>
     
    Funds
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports03/mf/rp-IN.html">Indian Mutual Funds</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports03/pms/rp-IN.html">Indian PMS</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-risk.html">US ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-sector.html">US Sector ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-country.html">Country $ ETFs</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-percent"></span>
     
    Fama-French
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-industry.html">Industry</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-factors.html">Factors</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-regression.html">Regressions</a>
    </li>
  </ul>
</li>
      </ul>
      <ul class="nav navbar-nav navbar-right">
        <li>
  <a href="https://stockviz.biz">
    <span class="fa fa-home"></span>
     
  </a>
</li>
<li>
  <a href="https://stockviz.substack.com">
    <span class="fa fa-envelope-o"></span>
     
  </a>
</li>
      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div id="header">



<h1 class="title toc-ignore">ZYDUSLIFE</h1>
<h3 class="subtitle">Equity Metrics</h3>
<h4 class="date">February 13, 2026</h4>

</div>


<div id="zydus-lifesciences-limited" class="section level1">
<h1>Zydus Lifesciences Limited</h1>
<p><a href="/reports01/index/industry/rp-Pharmaceuticals.html">Pharmaceuticals</a></p>
<div id="annual-returns" class="section level2">
<h2>Annual Returns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.ZYDUSLIFE.fan.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.ZYDUSLIFE.annret.png" /></p>
</div>
<div id="cumulative-returns-and-drawdowns" class="section level2">
<h2>Cumulative Returns and Drawdowns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.ZYDUSLIFE.cumret.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.ZYDUSLIFE.sma.cumret.png" /></p>
<p><br><br></p>
</div>
<div id="fundamentals" class="section level2">
<h2>Fundamentals</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.ZYDUSLIFE.eps.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.ZYDUSLIFE.RevenueFromOperations.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.ZYDUSLIFE.ebit.png" /></p>
<p><br><br></p>
</div>
<div id="ownership" class="section level2">
<h2>Ownership</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.ZYDUSLIFE.ownership.png" /></p>
<p><br><br></p>
</div>
<div id="margined" class="section level2">
<h2>Margined</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.ZYDUSLIFE.mtf.png" /></p>
<p><br><br></p>
<p><br />
</p>
</div>
<div id="ai-summary" class="section level2">
<h2>AI Summary</h2>
<p><em>asof: 2025-12-03 </em></p>
<div id="zydus-lifesciences-limited-zyduslife-analysis" class="section level3">
<h3>Zydus Lifesciences Limited (ZYDUSLIFE) Analysis</h3>
<p><strong>Current Context (Q2 FY26, as of Sep 2025):</strong> Zydus reported robust Q2 results with revenues of ₹61.2 Bn (+17% YoY), EBITDA ₹20.2 Bn (+38% YoY, margin 32.9%), and PAT ₹12.6 Bn (+38% YoY). H1 FY26 revenues ₹1.48 Tn (+18% YoY). US formulations (47% of revenue) grew 14% YoY; India formulations (25%) +9% (outpacing IPM); Consumer Wellness +31%; Intl Markets +39%. Recent USFDA tentative approval for Empagliflozin/Linagliptin combo (US$216 Mn market). Board approved ₹5,000 Cr fundraising (QIP/rights/etc.) for deleveraging and M&amp;A. Key acquisitions: Comfort Click (VMS digital) and Amplitude Surgical (MedTech).</p>
<div id="tailwinds-positive-catalysts" class="section level6">
<h6><strong>Tailwinds (Positive Catalysts)</strong></h6>
<ul>
<li><strong>Strong Execution &amp; Diversification:</strong> Multi-pronged growth across US generics/specialty (stable base + pipeline), India (leadership in oncology/chronic therapies, 44.5% chronic mix +670 bps YoY), Intl Markets (+39% YoY), Consumer Wellness (+31%, VMS entry via Comfort Click), and MedTech (Amplitude for ortho expansion).</li>
<li><strong>Margin Expansion:</strong> EBITDA margins at 32.9% (+500 bps YoY) due to scale, cost efficiencies, and high-margin segments (specialty, innovation).</li>
<li><strong>Robust Pipeline &amp; Launches:</strong> US: 25+ launches FY26, Saroglitazar PBC Phase 3 success (NDA Q4 FY26, US launch H2 CY26); CUTX-101 launch Jan-Jun 2026; 199 ANDAs (complex/FTF/Para IV). India: VaxiFlu, innovation-led growth. Vaccines/Biosimilars: WHO PQ, global tenders.</li>
<li><strong>Strategic Fundraising:</strong> ₹5,000 Cr for deleveraging (target net debt/EBITDA &lt;1x), US specialty/Europe M&amp;A.</li>
<li><strong>Acquisitions Synergies:</strong> Comfort Click (digital VMS, e-com leader in Europe); Amplitude (₹100 Cr ortho platform, robot launch).</li>
<li><strong>ESG Momentum:</strong> GHG intensity -58% vs. baseline; S&amp;P Global score 78/100; strong governance.</li>
</ul>
</div>
<div id="headwinds-challenges" class="section level6">
<h6><strong>Headwinds (Challenges)</strong></h6>
<ul>
<li><strong>US Generics Erosion:</strong> Revlimid sales sharply down (trailing Q3/Q4 FY26, full genericization Q4 FY26); Myrbetriq unpredictable pending court (Feb 2026). Base business stable but single-digit pricing erosion.</li>
<li><strong>Regulatory/Compliance:</strong> Recent USFDA VAI at oncology/Baddi facilities; ongoing inspections risk delays.</li>
<li><strong>Macro Pressures:</strong> US pricing regulations/tariffs uncertainty; forex volatility (US ~47% revenue).</li>
<li><strong>Integration Risks:</strong> New acquisitions (Comfort Click 1-mo, Amplitude 2-mo impact) added OpEx (+32% YoY); lower margins in VMS/MedTech.</li>
<li><strong>Competition Intensity:</strong> Crowded generics/specialty; Europe MedTech pricing erosion (3-4% periodic).</li>
</ul>
</div>
<div id="growth-prospects" class="section level6">
<h6><strong>Growth Prospects</strong></h6>
<table>
<colgroup>
<col width="24%" />
<col width="31%" />
<col width="44%" />
</colgroup>
<thead>
<tr class="header">
<th><strong>Segment</strong></th>
<th><strong>Key Drivers</strong></th>
<th><strong>Outlook (FY26-28)</strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>US (47%)</strong></td>
<td>30-35 ANDAs/yr; 15+ 505(b)(2); Saroglitazar PBC (~US$ multi-bn opp.); rare diseases (CUTX-101); organic + M&amp;A.</td>
<td>Mid-teens growth; specialty ramps FY27+.</td>
</tr>
<tr class="even">
<td><strong>India Formulations (25%)</strong></td>
<td>9%+ growth &gt;IPM; chronic/super-specialty leadership; 58 innovation products; hospital/e-com expansion.</td>
<td>Double-digit; chronic mix &gt;45%.</td>
</tr>
<tr class="odd">
<td><strong>Intl Markets (12%)</strong></td>
<td>+39% YoY; 48 brands &gt;US$1Mn; biosimilars/vaccines tenders; LiqMeds EU.</td>
<td>20%+ CAGR; RoW/EU focus.</td>
</tr>
<tr class="even">
<td><strong>Consumer Wellness (12%)</strong></td>
<td>+31%; Comfort Click (VMS digital, Europe/US); brands like Everyuth/Nutralite.</td>
<td>High-teens; global D2C scale.</td>
</tr>
<tr class="odd">
<td><strong>MedTech (~2%)</strong></td>
<td>Amplitude ortho (double-digit growth); Nephro facility FY26; Cardio (TAVI/stents).</td>
<td>3-yr scaling to 5-10% mix.</td>
</tr>
<tr class="even">
<td><strong>Overall</strong></td>
<td>FY26 guidance: 15-18% revenue growth, 26%+ EBITDA margins. Long-term: NCEs (Usnoflast ALS/UC), biosimilars (10 pipeline), vaccines (8 under dev).</td>
<td>15-20% CAGR to FY28; ROCE ~25%.</td>
</tr>
</tbody>
</table>
<p><strong>Catalysts:</strong> Saroglitazar US launch; fundraising M&amp;A; tender wins.</p>
</div>
<div id="key-risks" class="section level6">
<h6><strong>Key Risks</strong></h6>
<table>
<colgroup>
<col width="27%" />
<col width="40%" />
<col width="32%" />
</colgroup>
<thead>
<tr class="header">
<th><strong>Risk</strong></th>
<th><strong>Mitigants</strong></th>
<th><strong>Impact</strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Regulatory (USFDA/EU)</strong></td>
<td>16/41 sites inspected; strong track-record.</td>
<td>High: Delays in approvals/launches.</td>
</tr>
<tr class="even">
<td><strong>Pipeline/Execution</strong></td>
<td>Diversified (199 ANDAs, NCEs); partnerships.</td>
<td>Medium: Clinical failures (e.g., Saroglitazar NDA).</td>
</tr>
<tr class="odd">
<td><strong>US Concentration/Pricing</strong></td>
<td>Specialty shift; hedging.</td>
<td>High: Revlimid drop; erosion/tariffs.</td>
</tr>
<tr class="even">
<td><strong>M&amp;A Integration</strong></td>
<td>Experienced mgmt; LTIPs for key talent.</td>
<td>Medium: CCL/Amplitude OpEx drag.</td>
</tr>
<tr class="odd">
<td><strong>Debt/Leverage</strong></td>
<td>Fundraising deleverages (1-2x net debt/EBITDA).</td>
<td>Low-Medium: Capex heavy.</td>
</tr>
<tr class="even">
<td><strong>Forex/Competition</strong></td>
<td>40% INR revenue; differentiated portfolio.</td>
<td>Medium: Rupee volatility; generics crowding.</td>
</tr>
<tr class="odd">
<td><strong>Geopolitical/Macro</strong></td>
<td>Global footprint; ESG focus.</td>
<td>Low: Supply chain resilient.</td>
</tr>
</tbody>
</table>
<p><strong>Overall Outlook:</strong> <strong>Positive.</strong> Tailwinds from diversification, pipeline, and M&amp;A outweigh headwinds. Growth sustained at 15%+ via US specialty/Intl/MedTech. Risks manageable with strong balance sheet (post-fundraise) and execution history. Target ROCE 25%; monitor US court/inspections. <strong>Recommendation:</strong> Accumulate on dips for long-term compounding.</p>
</div>
</div>
</div>
</div>

&nbsp;
&nbsp;
<hr />
<p style="text-align: center;">Copyright &copy; 2023 SAS Data Analytics Pvt. Ltd. All rights reserved.</p>
<p style="text-align: center;"><a href="https://github.com/stockviz/reports/issues">&#x1F41E;</a></p>



</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
